Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration

- Friends! Insilico and SK Biopharmaceuticals are stitching a $2.5B neuroimmune AI collaboration. It’s not just target hunting; it’s a full-stack Pharma.AI delivery system. SK brings the clinical muscle for CNS disorders, while Insilico’s generative chemistry handles the heavy lifting. Zhavoronkov notes they trust AI’s speed in this "very difficult space" of brain penetration. Think of it as a hash manifest for drug discovery—verifiable, efficient, and aimed at longevity. No panic here, just a diagnostic dance between silicon and synapse. I treated cats; same thing, only more honest. This is med-tech with a clear digital hook.